AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
AstraZeneca Is Maintained at Outperform by BMO Capital
AstraZeneca Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Outperform on AstraZeneca, Raises Price Target to $82
BMO Capital analyst Etzer Darout maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $80 to $82.
AstraZeneca Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 8.85% BMO Capital $80 → $82 Maintains Outperform 04/16/2024 — Deutsche Bank Upgrades Sell → Ho
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Top 4 Health Care Stocks That May Plunge This Month
As of April 26, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicato
Barclays Raises AstraZeneca PT, Affirms at Overweight
Barclays on Friday raised the price target of British pharmaceutical company AstraZeneca (AZN.L, AZN.ST) to 135.00 pounds sterling from 130.00 pounds, while reiterating its overweight rating. Price (G
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)
Health Care Drops Amid Mixed Earnings -- Health Care Roundup
Health-care companies fell after mixed earnings. Bristol-Myers Squibb shares tumbled after the drug giant said it would lay off roughly 2,200 people in an effort to compensate for a slowdown in the s
Fusion Pharmaceuticals: AstraZeneca to Acquire All of Fusion's Shrs at $21 Each in Cash >FUSN
Fusion Pharmaceuticals: AstraZeneca to Acquire All of Fusion's Shrs at $21 Each in Cash >FUSN
Fusion Pharmaceuticals: Ontario Superior Court of Justice Issues Interim Order Regarding AstraZeneca Deal >FUSN
Fusion Pharmaceuticals: Ontario Superior Court of Justice Issues Interim Order Regarding AstraZeneca Deal >FUSN
Press Release: Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order PR Newswire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, April 2
The S&P 500 index initially closed down 0.5%, with the telecom sector falling 4%, and the worst performer—component Meta fell by about 10%, Google A fell 0.1%, the energy and raw materials sector rose 0.7%, and the Nasdaq 100 index initially closed down 0
The S&P 500 index initially closed down 0.5%, with the telecom sector falling 4%, and the worst performer—component Meta fell by about 10%, Google A fell 0.1%, the energy and raw materials sector rose 0.7%, and the Nasdaq 100 index initially closed down 0.5%. Component stock Meta led the decline. Microsoft fell more than 2%, Google A and Amazon were at the top of the decline, AMD rose 1.3%, Nvidia rose 3.6%, Tesla rose 5.1%, and AstraZeneca rose 5.5%. IBM initially closed down 8.3%, Caterpillar fell 7%, leading the decline in Dow constituent stocks, while Boeing rose about 1.7%, Merck
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks retreated late Thursday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) dro
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates.Caterpillar reported a first
Earnings Call Summary | AstraZeneca(AZN.US) Q1 2024 Earnings Conference
The following is a summary of the AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript:Financial Performance:AstraZeneca reported a revenue growth of 19% in Q1 2024, driven by significant product sa
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday's session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth a
European stock “Ocean Eleven” | SAP closed down more than 3%, Gucci's parent company fell about 2.8%, Sanofi rose about 4.5%, and AstraZeneca rose more than 5.9%
SAP closed down 3.05%, LVMH Group closed down 2.77%, Nestlé 2.02%, Roche Holdings closed down 1.53%, Novo Nordisk Copenhagen shares fell 1.35%, L'Oréal closed down 1.02%, Asmack Netherlands Amsterdam shares closed down 0.13%, GlaxoSmithKline London stock prices closed 0.28%, Novartis Pharmaceuticals closed up 4.47%, and AstraZeneca 5.94%.
Global Pulmonary Drugs Market Is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca,
No Data